Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Various Types of Dementias
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26401932
DOI
10.3233/jad-142898
PII: JAD142898
Knihovny.cz E-zdroje
- Klíčová slova
- 17β-HSD10, Alzheimer’s disease, amyloid-β peptides, biomarker, cerebrospinal fluid,
- MeSH
- 3-hydroxyacyl-CoA-dehydrogenasy mozkomíšní mok MeSH
- amyloidní beta-protein mozkomíšní mok MeSH
- demence mozkomíšní mok klasifikace MeSH
- ELISA MeSH
- kognitivní dysfunkce mozkomíšní mok MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty mozkomíšní mok MeSH
- proteiny tau mozkomíšní mok MeSH
- ROC křivka MeSH
- senioři MeSH
- věkové faktory MeSH
- záznam o duševním stavu MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- 3-hydroxyacyl-CoA-dehydrogenasy MeSH
- amyloid beta-protein (1-40) MeSH Prohlížeč
- amyloidní beta-protein MeSH
- HSD17B10 protein, human MeSH Prohlížeč
- peptidové fragmenty MeSH
- proteiny tau MeSH
BACKGROUND: Overexpression of the mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10, which is also known as the intracellular amyloid-β peptide (Aβ) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer's disease (AD). It appears that 17β-HSD10 may play a role in the pathogenesis of AD. OBJECTIVE: We investigated the possibility that levels of 17β-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. METHODS: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of Aβ(1- 42), tau, and phospho-tau. RESULTS: We found significantly higher levels of 17β-HSD10 in people with MCI due to AD (to 109.9% ), with AD (to 120.0% ), or with other types of dementia (to 110.9% ) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0% , and the specificity was 73.3% (compared to controls) or 52.5-59.1% (compared to other types of dementia). Results of multiple linear regression and of correlation analysis revealed AD-mediated changes in links between 17β-HSD10 and Mini Mental State Examination score. CONCLUSION: It seems that changes in 17β-HSD10 start many years before symptom onset, analogous to those in Aβ1 - 42, tau, or phospho-tau and that the levels are a relatively highly sensitive but unfortunately less specific biomarker of AD. A role of 17β-HSD10 overexpression in AD is discussed.
Institute of Computer Science Academy of Sciences Praha 8 Czech Republic
International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease
